Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 772

Sort by

Sort Order Select

Journal Articles

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Blood (2019) 134 (Supplement_1): 3828.

https://doi.org/10.1182/blood-2019-131303

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

Eunice S. Wang, MD, Elizabeth A. Griffiths, MD, Roland B. Walter, MD PhD MS, Martin S. Tallman, MD, Aaron D Goldberg, MD PhD, Boo Messahel, MD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 3829.

https://doi.org/10.1182/blood-2019-130536

Published: 2019

Journal Articles

Oral Arsenic Trioxide in Front Line Therapy for Acute Promyelocytic Leukemia. A Prospective Costa Rican Study

Mariela Rodriguez, MD, Ronald Rojas, Alejandra Vargas, MD, Miguel Angel Rodriguez, MD, Claudia Garcia, MD, Juliana Esquivel, MD, Jose Gerardo Rojas, MD, Willem Bujan Boza, MD

Blood (2019) 134 (Supplement_1): 3838.

https://doi.org/10.1182/blood-2019-122627

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

https://doi.org/10.1182/blood-2019-123819

Published: 2019

Journal Articles

Risk Adapted Therapeutic Strategy of Acute Myeloid Leukemia

Razan Mohty, MD, Radwan Massoud, BS, MD, Zaher Chakhachiro, MD, Rami Mahfouz, MD, Samer Nassif, MD, Jean Elcheikh, MD, Ali Bazarbachi, MD PhD

Blood (2019) 134 (Supplement_1): 3860.

https://doi.org/10.1182/blood-2019-125237

Published: 2019

Journal Articles

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Hongyan Tong, Docter, Xinping Zhou, Chen Mei, Jin Zhang, Ying Lu, Jianping Lan, MD, Shengyun Lin, Yuefeng Zhuang, Yuemin Kuang, Yanling Ren, Liya Ma, Juying Wei, Li Ye, Weilai Xu, Kongfei Li, Chenxi Lu, Jie Jin, MD PhD

Blood (2019) 134 (Supplement_1): 2594.

https://doi.org/10.1182/blood-2019-127675

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Yin Jie Koh, Michelle Poon, MBBS, MRCP, FRCPATH, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, FRCP, Elson Neo, Aloysius YL Ho, MBBS,FRCP,FRCPath, Lip Kun Tan, MBBS, FRCP, FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 4509.

https://doi.org/10.1182/blood-2019-125246

Published: 2019

Journal Articles

Streamline - Study of Relapse or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study

Amer M. Zeidan, MBBS, MHS, Adrienne Gilligan, PhD, Santosh Gautam, Nan Hu, David L. Grinblatt, Bhavik J. Pandya, PharmD

Blood (2019) 134 (Supplement_1): 5082.

https://doi.org/10.1182/blood-2019-123535

Published: 2019

Journal Articles

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Frieda Kontsioti, PhD, Eirini Maratou, PhD, Anthi Bouhla, MD, Vassiliki Mpakou, PhD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Eirini Glezou, MD, Thomas Thomopoulos, MD, Efthimia Bazani, MD, Sotirios Papageorgiou, MD PhD, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5176.

https://doi.org/10.1182/blood-2019-127501

Published: 2019

Journal Articles

Improved Outcomes of All-Trans-Retinoic Acid and Arsenic Trioxide Plus Idarubicin As a Frontline Treatment in Adult Patients with Acute Promyelocytic Leukemia

Shiwei Yang, Zunmin Zhu, Xiaojian Zhu, Yicheng Zhang

Blood (2019) 134 (Supplement_1): 5088.

https://doi.org/10.1182/blood-2019-128602

Published: 2019

Journal Articles

CBFA2T3-GLIS2 Fusion Gene Cause Dismal Clinical Course in Acute Megakaryocytic Leukemia of Down Syndrome

Nao Takasugi, Kenichi Amano, Yasuo Kubota, MD, Shota Kato, MD, Yuichi Mitani, MD, Junya Fujimura, MD PhD, Junko Takita, MD PhD, Mitsuteru Hiwatari, MD PhD

Blood (2019) 134 (Supplement_1): 5184.

https://doi.org/10.1182/blood-2019-129165

Published: 2019

Journal Articles

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Daniel Slade, MSc, BSc (Hons), Jenny Byrne, MD PhD, Kristian Brock, MSc, BSc, Hugues De Lavallade, Charles Craddock, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD, Matthew Smith, MBBS, Rebecca Bishop, BSc, Dragana Milojkovic, MBBS, MD, Christina Yap, MSci, PhD CStat

Blood (2019) 134 (Supplement_1): 497.

https://doi.org/10.1182/blood-2019-125591

Published: 2019

Journal Articles

Efficacy and Safety of DAC Combined with CAG Regimen (decitabine in combined with aclacinomycin, cytarabine and G-CSF) As a Second Induction Regimen Compared with Non-DAC Regimen for Acute Myeloid Leukemia Who Failed the First Course of Standard Induction IA Chemotherapy

Yili Chen, Min Dai, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 5104.

https://doi.org/10.1182/blood-2019-127947

Published: 2019

Journal Articles

Adult Case Series of Extramedullary Relapsing Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation in Whom a Rapid Response and a Reasonably Long Remission Could be Achieved with Gemtuzumab Ozogamycin (GO)

Omur Gokmen Sevindik, MD, Ali Ihsan Gemici, Furkan Selim Usta, Asli Çakır, Sevil Sadri, MD, Hüseyin Beköz, Fatma Deniz Sargın

Blood (2019) 134 (Supplement_1): 5129.

https://doi.org/10.1182/blood-2019-126195

Published: 2019

Journal Articles

Modified Conditioning Regimen with Idarubicin Prior to Autologous Hematopoietic Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphoma

Chen Tian, MD PhD, Yueyang Li, M. James You, MD PhD, Zhigang Zhao, Yizhuo Zhang, MD, Yafei WANG

Blood (2019) 134 (Supplement_1): 5349.

https://doi.org/10.1182/blood-2019-122089

Published: 2019

Journal Articles

Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach

Atte Nikkilä, MD, Olli Lohi, MD PhD, Ólafur Gísli Jónsson, MD PhD, Bendik Lund, MD PhD, Jonas Abrahamsson, Goda Elizabeta Vaitkeviciene, MD PhD, Kaie Pruunsild, MD, Mats Heyman, MD PhD, Hanne Vibeke Marquart, MD PhD, Kim Vettenranta, MD PhD, Kjeld Schmiegelow, MD PhD

Blood (2019) 134 (Supplement_1): 742.

https://doi.org/10.1182/blood-2019-122914

Published: 2019

Journal Articles

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

Corentin Orvain, Aline Tanguy-Schmidt, Sylvain Thepot, MD, Anne Bouvier, Benedicte Ribourtout, Franck Genevieve, Aurelien Giltat, Marion Champire, Adeline Chanson, Marielle Subileau, Damien Luque Paz, Valerie Ugo, Norbert Ifrah, Mathilde Hunault, MD PhD

Blood (2019) 134 (Supplement_1): 1310.

https://doi.org/10.1182/blood-2019-127351

Published: 2019

Journal Articles

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Wellington F Silva, MD, Lidiane Inês Da Rosa, MD, Fernanda S Seguro, MD, Douglas R. A. Silveira, Luciana Nardinelli, M.Sc, Valeria Buccheri, MD PhD, Elvira DRP Velloso, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1354.

https://doi.org/10.1182/blood-2019-127202

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

Oral Arsenic Trioxide in Front Line Therapy for Acute Promyelocytic Leukemia. A Prospective Costa Rican Study

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Risk Adapted Therapeutic Strategy of Acute Myeloid Leukemia

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Streamline - Study of Relapse or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Improved Outcomes of All-Trans-Retinoic Acid and Arsenic Trioxide Plus Idarubicin As a Frontline Treatment in Adult Patients with Acute Promyelocytic Leukemia

CBFA2T3-GLIS2 Fusion Gene Cause Dismal Clinical Course in Acute Megakaryocytic Leukemia of Down Syndrome

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Efficacy and Safety of DAC Combined with CAG Regimen (decitabine in combined with aclacinomycin, cytarabine and G-CSF) As a Second Induction Regimen Compared with Non-DAC Regimen for Acute Myeloid Leukemia Who Failed the First Course of Standard Induction IA Chemotherapy

Adult Case Series of Extramedullary Relapsing Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation in Whom a Rapid Response and a Reasonably Long Remission Could be Achieved with Gemtuzumab Ozogamycin (GO)

Modified Conditioning Regimen with Idarubicin Prior to Autologous Hematopoietic Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphoma

Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only